Modified growth-hormone fragment · Fact sheet
AOD-9604
Also known as AOD9604 · Tyr-hGH 177–191
AOD-9604 is a modified fragment of human growth hormone investigated for fat metabolism. Human safety studies do not establish the fat-loss and joint-repair benefits often associated with it, and it is not FDA approved.
What is AOD-9604?
AOD-9604 is a short synthetic fragment, not full-length human growth hormone. Its development aimed to separate effects on fat metabolism from other growth-hormone effects.
Benefits people look for
Interest centers on fat loss without the broader effects of growth hormone, and on claims about cartilage or injury recovery. These are separate claims and need separate human outcome evidence.
What the evidence supports
- Controlled human exposure has been studied; the cited safety analysis reported generally similar tolerability to placebo under study conditions.
- That finding cannot establish clinical benefit or the safety of different products and routes.
All research areas
- Obesity
- Fat metabolism
- Short-term tolerability
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- FDA identifies immune-response and impurity concerns and insufficient safety information.
- The available studies cannot reliably exclude uncommon or long-term harms.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Limited or unclear evidenceA published analysis pools six controlled human studies to discuss tolerability. It is not proof of effective weight reduction or joint repair, and the authors had development-company affiliations.
Selected research to read
Pooled safety analysis of six controlled trials; development-company conflicts and route limits matter.
FDA approval & research status
AOD-9604 has no FDA-approved therapeutic product. FDA compounding committee consideration is a separate process and does not authorize weight-loss or recovery claims.
No FDA-approved use is documented in the records summarized on this page.
No FDA-approved product
AOD-9604 has no FDA-approved therapeutic product. FDA compounding committee consideration is a separate process and does not authorize weight-loss or recovery claims.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Durable, meaningful weight-loss benefit
- Human joint-repair outcomes
- Safety across formulations and routes
The takeaway
AOD-9604 has human research history, but the evidence reviewed here does not establish it as a weight-loss or recovery treatment.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA: safety concerns for selected bulk substances
Ingredient-specific safety findings; compounding review is not drug approval.
- 2journalAOD-9604 human safety and tolerability analysis
Pooled safety analysis of six controlled trials; development-company conflicts and route limits matter.
- 3fdaFDA advisory committee: AOD-9604 review
December 2024 meeting summary documenting consideration of AOD-9604 for the compounding bulks list.